These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 37606641)

  • 1. Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study.
    Casanova M; Bautista F; Campbell-Hewson Q; Makin G; Marshall LV; Verschuur AC; Cañete Nieto A; Corradini N; Ploeger BA; Brennan BJ; Mueller U; Zebger-Gong H; Chung JW; Geoerger B
    Clin Cancer Res; 2023 Nov; 29(21):4341-4351. PubMed ID: 37606641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation.
    Metts JL; Trucco M; Weiser DA; Thompson P; Sandler E; Smith T; Crimella J; Sansil S; Thapa R; Fridley BL; Llosa N; Badgett T; Gorlick R; Reed D; Gill J
    Cancer Med; 2023 Feb; 12(4):4270-4281. PubMed ID: 36151773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anlotinib, Vincristine, and Irinotecan for Advanced Ewing Sarcoma After Failure of Standard Multimodal Therapy: A Two-Cohort, Phase Ib/II Trial.
    Xu J; Xie L; Sun X; Liu K; Tang X; Yan T; Yang R; Guo W; Gu J
    Oncologist; 2021 Jul; 26(7):e1256-e1262. PubMed ID: 33611805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized Phase II Trial of Vincristine-Irinotecan With or Without Temozolomide, in Children and Adults With Relapsed or Refractory Rhabdomyosarcoma: A European Paediatric Soft Tissue Sarcoma Study Group and Innovative Therapies for Children With Cancer Trial.
    Defachelles AS; Bogart E; Casanova M; Merks JHM; Bisogno G; Calareso G; Gallego Melcon S; Gatz SA; Le Deley MC; McHugh K; Probst A; Rocourt N; van Rijn RR; Wheatley K; Minard-Colin V; Chisholm JC
    J Clin Oncol; 2021 Sep; 39(27):2979-2990. PubMed ID: 34343032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vincristine, irinotecan, and temozolomide treatment for refractory/relapsed pediatric solid tumors: A single center experience.
    Büyükkapu Bay S; Kebudi R; Görgün O; Zülfikar B; Darendeliler E; Çakır FB
    J Oncol Pharm Pract; 2019 Sep; 25(6):1343-1348. PubMed ID: 30080131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longer versus Shorter Schedules of Vincristine, Irinotecan, and Temozolomide (VIT) for Relapsed or Refractory Ewing Sarcoma: A Randomized Controlled Phase 2 Trial.
    Xu J; Xie L; Sun X; Liu K; Liang X; Cai Z; Tang X; Guo W
    Clin Cancer Res; 2023 Mar; 29(6):1040-1046. PubMed ID: 36622702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group.
    Pappo AS; Lyden E; Breitfeld P; Donaldson SS; Wiener E; Parham D; Crews KR; Houghton P; Meyer WH;
    J Clin Oncol; 2007 Feb; 25(4):362-9. PubMed ID: 17264331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignancies.
    Geoerger B; Morland B; Jiménez I; Frappaz D; Pearson ADJ; Vassal G; Maeda P; Kincaide J; Mueller U; Schlief S; Teufel M; Ploeger BA; Cleton A; Agostinho AC; Marshall LV
    Eur J Cancer; 2021 Aug; 153():142-152. PubMed ID: 34157616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vincristine, Irinotecan, and Temozolomide as a Salvage Regimen for Relapsed or Refractory Sarcoma in Children and Young Adults.
    Ju HY; Park M; Lee JA; Park HJ; Park SY; Kim JH; Kang HG; Yang HC; Park BK
    Cancer Res Treat; 2022 Apr; 54(2):563-571. PubMed ID: 34126703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412.
    Davis KL; Fox E; Isikwei E; Reid JM; Liu X; Minard CG; Voss S; Berg SL; Weigel BJ; Mackall CL
    Clin Cancer Res; 2022 Dec; 28(23):5088-5097. PubMed ID: 36190525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma.
    Raciborska A; Bilska K; Drabko K; Chaber R; Pogorzala M; Wyrobek E; Polczyńska K; Rogowska E; Rodriguez-Galindo C; Wozniak W
    Pediatr Blood Cancer; 2013 Oct; 60(10):1621-5. PubMed ID: 23776128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors.
    Mascarenhas L; Ogawa C; Laetsch TW; Weigel BJ; Bishop MW; Krystal J; Borinstein SC; Slotkin EK; Muscal JA; Hingorani P; Levy DE; Mo G; Shahir A; Wright J; DuBois SG
    Cancer Med; 2021 Feb; 10(3):843-856. PubMed ID: 33474828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of life and Q-TWiST were not adversely affected in Ewing sarcoma patients treated with combined anlotinib, irinotecan, and vincristine: (Peking University People's Hospital Ewing sarcoma trial-02, PKUPH-EWS-02).
    Dong S; Sun K; Xie L; Xu J; Sun X; Ren T; Huang Y; Yang R; Tang X; Yang F; Gu J; Guo W
    Medicine (Baltimore); 2021 Dec; 100(51):e28078. PubMed ID: 34941047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312).
    Cole KA; Pal S; Kudgus RA; Ijaz H; Liu X; Minard CG; Pawel BR; Maris JM; Haas-Kogan DA; Voss SD; Berg SL; Reid JM; Fox E; Weigel BJ
    Clin Cancer Res; 2020 Mar; 26(6):1213-1219. PubMed ID: 31857431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors.
    Yoon JH; Kwon MM; Park HJ; Park SY; Lim KY; Joo J; Park BK
    BMC Cancer; 2014 Aug; 14():622. PubMed ID: 25164234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network.
    Amoroso L; Castel V; Bisogno G; Casanova M; Marquez-Vega C; Chisholm JC; Doz F; Moreno L; Ruggiero A; Gerber NU; Fagioli F; Hingorani P; Melcón SG; Slepetis R; Chen N; le Bruchec Y; Simcock M; Vassal G
    Eur J Cancer; 2020 Aug; 135():89-97. PubMed ID: 32554315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411).
    Schafer ES; Rau RE; Berg SL; Liu X; Minard CG; Bishop AJR; Romero JC; Hicks MJ; Nelson MD; Voss S; Reid JM; Fox E; Weigel BJ; Blaney SM
    Pediatr Blood Cancer; 2020 Feb; 67(2):e28073. PubMed ID: 31724813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
    Mody R; Naranjo A; Van Ryn C; Yu AL; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Sondel PM; Bender JG; Maris JM; Park JR; Bagatell R
    Lancet Oncol; 2017 Jul; 18(7):946-957. PubMed ID: 28549783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of bevacizumab plus irinotecan in pediatric patients with recurrent/refractory solid tumors.
    Okada K; Yamasaki K; Tanaka C; Fujisaki H; Osugi Y; Hara J
    Jpn J Clin Oncol; 2013 Nov; 43(11):1073-9. PubMed ID: 24002900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors.
    Wagner L; Turpin B; Nagarajan R; Weiss B; Cripe T; Geller J
    Pediatr Blood Cancer; 2013 Sep; 60(9):1447-51. PubMed ID: 23630159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.